Thiophene, 2-methyl-4-propyl

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: Thiophene, 2-methyl-4-propyl
• 英文别名: 2-methyl-4-propylthiophene
• 化学式: C₈H₁₂S
• 分子量: 140.25
• InChiKey: YDSZTMAXFCQKIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• THERAPEUTIC SUBSTITUTED PYRROLES
  申请人：Allergan, Inc.

  公开号：US20150336940A1

  公开（公告）日：2015-11-26

  Disclosed herein are compounds of the formula: compositions thereof, and methods for the treatment of glaucoma, reducing intraocular pressure, and other prostaglandin EP 2 mediated disease and disorders.

  本文披露了以下公式的化合物：其组合物以及治疗青光眼、降低眼内压和其他前列腺素EP2介导的疾病和紊乱的方法。
• GLUCOPYRANOSIDE COMPOUND
  申请人：NOMURA Sumihiro

  公开号：US20120258913A1

  公开（公告）日：2012-10-11

  A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH 2 ) n — (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  一种化合物的公式：其中环A和环B是：(1) 环A是一个可选取代的不饱和单环杂环，环B是一个可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环，(2) 环A是一个可选取代的苯环，环B是一个可选取代的不饱和单环杂环或可选取代的不饱和融合杂双环，或(3) 环A是一个可选取代的不饱和融合杂双环，环B是独立的可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；X是一个碳原子或氮原子；Y是—(CH2)n—(n为1或2)；或其药学上可接受的盐或前药。
• 5-flurorouracil derivatives
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0247381A2

  公开（公告）日：1987-12-02

  This invention relates to a 5-fluorouracil derivative represented by the formula wherein RY is a hydrogen atom or a specific acyl group, Z is a phenyl-lower alkoxy-lower alkyl group, thienyl-lower alkyl group optionally substituted with halogen atom on the thienyl ring, or a group wherein R1 and R2 are each a hydrogen atom, a specific acyl group, phenyl-lower alkyl group having a group RxOCO- on the phenyl ring, or a group -(A)nB, R" being a specific organic group, A being a lower alkylene group, n being 0 or 1, and B being a 5- or 6-membered unsaturated heterocyclic group having 1 to 4 hetero-atoms selected from nitrogen, oxygen and sulfur and optionally having a benzene ring, naphthalene ring or pyridine ring condensed therewith, with the proviso that when R is a hydrogen atom or acyl group, R2 is not a hydrogen atom or acyl group; to a process for preparing the same; to an anticancer composition comprising an effective amounts of the same; and to use of the same for preparation of an anticancer composition.

  本发明涉及一种 5-氟尿嘧啶衍生物，其式如下 其中 RY 是氢原子或特定酰基，Z 是苯基-低级烷氧基-低级烷基，噻吩基-低级烷基，可选择在噻吩基环上被卤素原子取代，或一个基团 其中 R1 和 R2 分别是氢原子、特定的酰基、苯基环上带有基团 RxOCO- 的苯基-低级烷基或基团-(A)nB，R "是特定的有机基团，A 是低级亚烷基，n 是 0 或 1、和 B 是 5 或 6 元不饱和杂环基团，具有 1 至 4 个选自氮、氧和硫的杂原子，并可选具有苯环、萘环或吡啶环，但当 R 是氢原子或酰基时，R2 不是氢原子或酰基；制备上述物质的工艺；包含有效量上述物质的抗癌组合物；以及使用上述物质制备抗癌组合物。
• Novel compounds having inhibitory activity against sodium-dependant glucose transporter
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2896397A1

  公开（公告）日：2015-07-22

  Use of a compound of formula (IA): wherein RA is a halogen atom, a lower alkyl group or a lower alkoxy group; RB is a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a mono- or di-lower alkylamino group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a mono- or di-lower alkylamino group; and Rc is hydrogen atom; or RB and RC taken together are a fused benzene ring which may be substituted by a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; in combination with another antidiabetic agent, an anti-obesity agent, an antihypertensive agent, an antiplatelet agent, an anti-atherosclerotic agent and/or a hypolipidemic agent, in the manufacture of a medicament for the treatment of diabetes mellitus (type 1 and type 2), diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, postprandial hyperglycemia, or delayed wound healing.

  使用式(IA)化合物： 其中 RA 是卤素原子、低级烷基或低级烷氧基；RB 是任选被卤素原子、氰基、低级烷基、卤代低级烷基、低级烷氧基、卤代低级烷氧基或单或双低级烷基氨基取代的苯基；或可被卤素原子、氰基、低级烷基、卤代低级烷基、低级烷氧基、卤代低级烷氧基或单低或双低烷基氨基取代的杂环基团；且 Rc 为氢原子；或 RB 和 RC 合在一起为可被卤素原子、低级烷基、卤代低级烷基、低级烷氧基或卤代低级烷氧基取代的融合苯环； 与另一种抗糖尿病药、抗肥胖药、抗高血压药、抗血小板药、抗动脉粥样硬化药和/或降血脂药联用、 用于制造治疗糖尿病（1 型和 2 型）、糖尿病视网膜病变、糖尿病神经病变、糖尿病肾病、餐后高血糖或伤口延迟愈合的药物。
• PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS
  申请人：Novartis AG

  公开号：EP1551827B1

  公开（公告）日：2009-12-02